Keytruda, a most cancers immunotherapy from Merck that has change into the world's best-selling drug, is given as an intravenous infusion over half-hour. The pharmaceutical big now has outcomes from a pivotal scientific trial exhibiting that an experimental injectable model of Keytruda, dosed in minutes, was roughly corresponding to the IV-administered drug. Merck now plans to debate these outcomes with regulators, laying the groundwork for potential submissions searching for approval for the extra patient-friendly subcutaneous model.

The injectable Keytruda may enhance entry to the product with a model that’s much less burdensome for each sufferers and medical doctors. For Merck, an injectable formulation would assist the corporate retain some market share and income that will probably be misplaced when biosimilar variations of the drug change into accessible. In pursuing an injectable model of its blockbuster most cancers drug, Merck is following the identical technique as another pharmaceutical corporations that additionally face looming competitors within the biosimilar house.

Pembrolizumab, model identify Keytruda, belongs to a category of immunotherapies referred to as checkpoint inhibitors. The drug is an antibody designed to dam PD-1, a protein on immune cells that retains these cells from recognizing and focusing on tumors. Antibody medicine are sometimes administered as IV infusions. Merck developed the injectable model of Keytruda with enzyme know-how that permits intravenous medicine to be administered as injections. This know-how, referred to as Hybrozyme, comes from South Korea-based Alteogen.

The outcomes introduced Tuesday are from an open-label Section 3 trial that enrolled roughly 378 adults with superior non-small cell lung most cancers. Keytruda was evaluated as a first-line remedy. Sufferers had been randomly assigned to obtain injectable Keytruda together with chemotherapy or IV-infused Keytruda and chemotherapy. Each drug regimens had been administered each six weeks. The principle objective was to evaluate pharmacokinetics (PK) – how the drug is distributed within the physique.

With out releasing particular numbers, Merck mentioned the injectable Keytruda met the examine's two key PK targets, demonstrating in-body publicity no worse than the IV-infused formulation of the drug throughout the first dosing cycle and at Keytruda's trough focus measured on the regular state of the drug. Concerning the secondary targets of efficacy and security, Merck mentioned the subcutaneous formulation was per the IV formulation. Merck mentioned these outcomes, plus knowledge from ongoing analyses, will probably be introduced at an unspecified medical assembly and shared with regulatory authorities all over the world.

“It is extremely encouraging to see optimistic Section 3 outcomes evaluating this fastened dose mixture of subcutaneous pembrolizumab, which was administered on common in roughly two to 3 minutes and has the potential to enhance the affected person expertise and improve affected person entry . and healthcare suppliers in contrast with intravenous administration,” mentioned Marjorie Inexperienced, senior vp and head of oncology, world scientific improvement, Merck Analysis Laboratories, in a ready assertion.

Keytruda had revenues of $21.6 billion within the first three quarters of 2024, a rise of 17.6% in comparison with the identical interval final yr. It’s by far Merck's largest product when it comes to gross sales and likewise the best-selling drug on the planet. The patent on the Keytruda drug expires in 2028.

Merck isn't the one firm that has used Alteogen's know-how as a method to compete with biosimilars. Earlier this month, Daiichi Sankyo secured the rights to make use of the know-how to develop a subcutaneous model of Enhertu, a profitable antibody drug most cancers remedy being marketed in partnership with AstraZeneca. However Alteogen additionally has alliances with corporations that develop biosimilars. Sandoz has world rights to make use of the Alteogen know-how to develop a subcutaneous model of an unspecified biosimilar in its portfolio. That deal consists of an choice for Sandoz to license the know-how for 2 further merchandise.

Roche has already obtained FDA approvals for brand new injectable formulations of two of its blockbuster merchandise. In September, the FDA permitted an injectable model of the pharmaceutical big's most cancers immunotherapy Tecentriq. That approval was adopted by a regulatory nod for an injectable formulation of the a number of sclerosis drug Ocrevus. Each Roche merchandise are developed with Enhanze, a Halozyme drug supply know-how that permits organic medicine to be delivered as injections.

Picture: Christopher Occhicone/Bloomberg through Getty Pictures